Clearside Biomedical (CLSD)

Clearside Biomedical Stock Analysis & Ratings

CLSD Stock Chart & Stats

Day’s Range$1.31 - $1.49
52-Week Range$1.30 - $7.73
Previous Close$1.45
Average Volume (3M)820.62K
Market Cap$83.01M
P/E Ratio-127.8
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-0.01



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $1.30 and its highest was $7.73 in the past 12 months.
    What is Clearside Biomedical’s market cap?
    Clearside Biomedical’s market cap is $83.01M.
      What is Clearside Biomedical’s price target?
      The average price target for Clearside Biomedical is $9.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $10.00 ,the lowest forecast is $9.00. The average price target represents 600.72% Increase from the current price of $1.38.
        What do analysts say about Clearside Biomedical?
        Clearside Biomedical’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Clearside Biomedical’s upcoming earnings report date?
          Clearside Biomedical’s upcoming earnings report date is Aug 10, 2022 which is in 81 days.
            How were Clearside Biomedical’s earnings last quarter?
            Clearside Biomedical released its earnings results on May 11, 2022. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.1.
              Is Clearside Biomedical overvalued?
              According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
                Does Clearside Biomedical pay dividends?
                Clearside Biomedical does not currently pay dividends.
                What is Clearside Biomedical’s EPS estimate?
                Clearside Biomedical’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Clearside Biomedical have?
                Clearside Biomedical has 60,150,000 shares outstanding.
                  What happened to Clearside Biomedical’s price movement after its last earnings report?
                  Clearside Biomedical reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -6.207%.
                    Which hedge fund is a major shareholder of Clearside Biomedical?
                    Among the largest hedge funds holding Clearside Biomedical’s share is Caxton Associates LP. It holds Clearside Biomedical’s shares valued at N/A.


                      Clearside Biomedical Stock Analysis

                      Smart Score
                      Price Target
                      ▲(600.72% Upside)
                      Strong Buy
                      The Clearside Biomedical stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Clearside Biomedical

                      Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

                      Similar Stocks
                      Price & Change
                      Selecta Biosciences
                      Reata Pharmaceuticals
                      Syndax Pharmaceuticals

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis